Since first introduced in the 1990s, angiotensin receptor blockers (ARBs) have been widely used in management of patients with hypertension and heart failure. 1 The main mechanisms of action of ARBs are believed to be secondary to afterload reduction and modifying left ventricular remodeling in patients with heart failure as a result of blocking the angiotensin type 1 receptor in vascular smooth muscle and myocardium. 2, 3 Current guidelines recommend the use of ARBs in the management of heart failure and/or hypertension in patients who are intolerant to angiotensin converting enzyme inhibitors. [4] [5] [6] The American College of Cardiology and the American Heart Association have endorsed similar recommendations for the management of hypertension in those aged 65 years or older, which is the population commonly affected with hypertension. 7 Several randomized trials and meta-analyses had demonstrated that ARBs reduce cardiovascular morbidity and mortality [8] [9] [10] ; however, none of these studies targeted primarily older patients. In addition to that, ARBs are known to be well tolerated, 11-13 yet side effects, namely hypotension, acute kidney injury, and hyperkalemia, are associated with their use. 14 The incidence of these side effects is believed to be higher in older patients. 15 Given the limitations of the currently available data and the frequency of prescribing ARBs, we conducted this comprehensive meta-analysis to assess the effects of ARBs on a wide range of outcomes to get a more complete understanding of the benefits and harms of ARBs in older patients.
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Since first introduced in the 1990s, angiotensin receptor blockers (ARBs) have been widely used in management of patients with hypertension and heart failure. 1 The main mechanisms of action of ARBs are believed to be secondary to afterload reduction and modifying left ventricular remodeling in patients with heart failure as a result of blocking the angiotensin type 1 receptor in vascular smooth muscle and myocardium. 2, 3 Current guidelines recommend the use of ARBs in the management of heart failure and/or hypertension in patients who are intolerant to angiotensin converting enzyme inhibitors. [4] [5] [6] The American College of Cardiology and the American Heart Association have endorsed similar recommendations for the management of hypertension in those aged 65 years or older, which is the population commonly affected with hypertension. 7 Several randomized trials and meta-analyses had demonstrated that ARBs reduce cardiovascular morbidity and mortality [8] [9] [10] ; however, none of these studies targeted primarily older patients. In addition to that, ARBs are known to be well tolerated, [11] [12] [13] yet side effects, namely hypotension, acute kidney injury, and hyperkalemia, are associated with their use. 14 The incidence of these side effects is believed to be higher in older patients. 15 Given the limitations of the currently available data and the frequency of prescribing ARBs, we conducted this comprehensive meta-analysis to assess the effects of ARBs on a wide range of outcomes to get a more complete understanding of the benefits and harms of ARBs in older patients.
Methods data sources
A computerized literature search of the MEDLINE database, without language restriction, was conducted from inception until October 2013 for randomized clinical trials using the search strategy shown in Figure 1 .
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Background
The efficacy and safety of angiotensin receptor blockers (ARBs) in the older population is unclear.
oBjectives
To determine the efficacy and safety of ARBs in older patients.
Methods
Randomized trials that compared ARBs to control and reported clinical outcomes in patients with a mean age of 65 years or older were included. Random-effects summary risk ratios (RRs) were constructed.
results
A total of 16 trials met our selection criteria, which yielded 113,386 patients. ARBs were associated with a marginal increased risk of allcause mortality (RR: 1.03, 95% confidence interval (CI): 1.00-1.06, P = 0.05), a nonsignificant increased risk of myocardial infarction (RR: 1.04, 95% CI: 0.96-1.12, P = 0.36), a marginal reduction in heart failure hospitalization (RR: 0.86, 95% CI: 0.74-1.00, P = 0.06), and a significant reduction in the risk of stroke (RR: 0.93, 95% CI: 0.87-0.99, P = 0.03). ARBs were associated with an increased risk of acute kidney injury (RR: 1.48, 95% CI: 1.24-1.77, P < 0.001), hypotension (RR: 1.56, 95% CI: 1.24-1.97, P < 0.001), and hyperkalemia (RR: 1.57, 95% CI: 1.13-2.19, P = 0.008). On the sensitivity analysis including placebo-controlled trials, the risk of all-cause mortality was no longer significant (P = 0.2), while the remainder of the outcomes did not change.
selection criteria
We selected studies that reported clinical outcomes in which patients were randomized to receive either ARBs or a control agent; the control agent could be placebo, usual care, or another class of antihypertensive medications (e.g., betablockers or calcium antagonists). We required the mean age of the patients in the studies to be 65 years or older. We excluded studies that were published in abstract form or only reported noncardiovascular outcomes (e.g., cognitive impairment or microalbuminuria). We included only the studies that enrolled at least 1,000 patients and had a mean follow-up duration of at least 12 months.
data extraction
Two reviewers (I.Y.E. and V.C.) independently extracted data on study design, sample characteristics, sample size, intervention strategies, outcome measures, and other study characteristics from the included randomized-controlled trials using a standardized form. Any discrepancies were resolved by consensus of the authors. For all clinical outcomes, we tabulated the number of events that occurred in each arm of each trial.
outcomes and definitions
The efficacy outcomes that we tested were all-cause mortality, nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization for heart failure, while acute kidney injury, hypotension, and hyperkalemia were assessed as safety outcomes.
All-cause mortality was defined as death from any cause. MI was defined in 3 studies as an increase in the cardiac markers (cardiac troponin and/or creatinine kinase-MB fraction) and electrocardiographic changes suggestive of MI (new Q-waves in 2 or more contiguous leads, new left bundle branch block, or ischemic ST-T wave changes) or typical clinical presentation consistent with MI as ischemic chest pain for more than 20 minutes, pulmonary edema, or cardiogenic shock not otherwise explained. 10, 13, 16 Four studies defined heart failure hospitalization as an admission to the hospital necessitated by heart failure and primarily for its treatment (i.e., symptoms or signs of worsening heart failure). 10, 13, 16, 17 Two studies used a new focal neurological deficit that was thought to be of vascular origin with signs or symptoms lasting longer than 24 hours as the definition of stroke. 13, 17 Doubling of serum creatinine and potassium level of more than 5.5 mg/dl were the cutoff for several studies in defining acute kidney injury and hyperkalemia, respectively. 10, 13, 16, [18] [19] [20] [21] Six studies identified hypotension resulting in symptoms (e.g., dizziness) as the definition of hypotension. 10, 13, 19, [21] [22] [23] 
statistical analysis
We analyzed outcomes by the intention to treat analysis. We used a DerSimonian and Laird model to construct the random-effects summary risk ratio (RR). 24 We quantified statistical heterogeneity for each outcome of interest by using the Cochran Q test and the I 2 statistic. 25 I 2 statistic values <25%, 25%-50%, and >50% were considered as low, moderate, and high degree of heterogeneity, respectively. 26 Publication bias was measured by Egger's methods. 27 We followed the PRISMA statement for conducting a high-quality meta-analysis. 28 Trial quality was assessed based on the description of treatment allocation, assessment of the blinded outcome, and description of losses to follow-up. 29 All P values were 2-tailed, with statistical significance set at 0.05, and confidence intervals 72 (7) 72 (7 (CIs) were calculated at the 95% level for the overall estimates effect. All analyses were performed using STATA software version 11 (STATA Corporation, College Station, TX).
sensitivity analyses
In our primary analysis, all ARBs were combined regardless of the dose, assuming a class effect and analyzed regardless of the type of control. We conducted a secondary stratified analysis to compare ARBs vs. placebo. We performed a further analysis comparing ARBs to placebo in the heart failure trials. 30, 31 and only 1 trial used a beta-blocker as the control. 34 Six ARBs (candesartan, valsartan, losartan, telmisartan, irbesartan, and eprosartan) were included in this meta-analysis; candesartan was the most frequently tested. 10, 17, 18, 32 The main indication for ARB was heart failure. 10, 12, 16, 20, 23, 33 The overall mean age of the patients in the ARB group and the control group was 68 ± 3 years, and 61% were men. Duration of follow-up ranged from 12 to 58 months (mean 39 ± 14 months). The mean blood pressure at baseline was 141 (±14)/82 (±7) mm Hg in the ARB group vs. 142 (±14)/82 (±7) mm Hg in the control group. At the end of the studies, the mean blood pressure was 138 (±6)/79 (±2) mm Hg in the ARB group vs. 140 (±6)/80 (±1) mm Hg in the control group. Diabetic patients, smokers, and patients being treated for hyperlipidemia comprised from 0% to 39%, 7% to 39%, and 9% to 62% of the enrollees, respectively. Baseline characteristics, mean blood pressure at baseline and at the end of the studies, and follow-up duration are reported in Table 1 . Measures of study quality are shown in Table 2 .
sensitivity analysis
Eight trials using placebo as the control were included in the sensitivity analysis. 10, 13, 16, [18] [19] [20] 22, 32 The total number of patients in this analysis were 50,522, with 25,101 patients in the ARB group and 25,421 in the placebo group.
efficacy and safety outcomes
In Table 3 , we report the random-effects model for efficacy and safety outcomes in the ARB group vs. the control group. Table 4 reports the random-effects model for the same outcomes when the ARB group was compared to the placebo group. There was no evidence of publication bias for any outcome with Egger's test. Table 5 demonstrates the random-effects model for efficacy and safety outcomes in the ARB group vs. the placebo in the heart failure trials. In Supplementary Table A, we report the RR for the efficacy and safety outcomes in the ARB group vs. control group according to the indication for which ARBs were used. In Supplementary Table B, we report the RR for the efficacy and safety outcomes in the ARB group vs. placebo according to the indication for which ARBs were used. discussion Our analysis of 16 randomized trials in 113,386 older patients (with mean age 68 ± 3 years) demonstrated that ARBs modestly reduced the risk of stroke in this population (the number needed to treat = 200). Moreover, there were no (or weak) associations for all-cause mortality and myocardial infarction. Hospitalization for heart failure was only reduced among the heart failure cohort. With regard to side effects, ARBs were significantly associated with increased Abbreviations: ARB, angiotensin receptor blocker; CI, confidence interval; MI, myocardial infarction; RR, risk ratio. risk of acute kidney injury (number needed to harm = 333), hypotension (number needed to harm = 77), and hyperkalemia (number needed to harm = 200) when compared to control or placebo. These findings are mainly applicable to older patients with a history of heart failure. In a Cochrane review by Heran et al., 35 the authors showed that ARBs did not reduce total mortality (RR: 0.87, 95% CI: 0.76-1.00) when compared to placebo in patients with heart failure and reduced ejection fraction. Additionally, ARBs did not reduce total mortality (RR: 1.02, 95% CI: 0.93-1.12) in heart failure patients with preserved ejection fraction. In a meta-analysis conducted by Savarese et al. 8 among high risk patients without heart failure, ARBs significantly reduced the composite outcome of cardiovascular death, MI, and stroke (odds ratio: 0.92, 95% CI: 0.87-0.98; P = 0.005); however, ARBs did not reduce the risk of cardiovascular mortality separately (odds ratio: 1.03, 95% CI: 0.85-1.26; P = 0.748) or all-cause mortality (odds ratio: 1.01, 95% CI: 0.94-1.08; Our analysis showed that ARBs were associated with a marginal increase in all-cause mortality when compared to an active agent but not when compared to placebo in older patients. The loss of association on the sensitivity analysis may reflect a reduction in power of a very small treatment effect, which may not be clinically relevant; however, the small hazard was directionally in line with the cumulative effects of hypotension, acute kidney injury, and hyperkalemia. ARBs are believed to exert a neuroprotective effect beyond blood pressure reduction that reduces the risk of stroke. 32, 34 The results from our analysis further support this. It is important to mention that our analysis did not address the dose or duration of ARB therapy that is associated with the reduction in the stroke risk. Caldeira et al. 14 studied the tolerability of ARBs in patients who are intolerant to angiotensin converting enzyme inhibitors. They observed that the risk of hypotension (RR: 2.63; 95% CI: 1.77-3.92), renal dysfunction (RR: 2.07; 95% CI: 1.45-2.95), and hyperkalemia (RR: 3.37; 95% CI: 1.60-7.11) were more frequent with ARBs when compared to placebo. In our analysis, which was limited to older patients, ARBs were significantly associated with a risk of acute kidney injury, hypotension, and hyperkalemia when compared to an active agent or placebo. Although our study did not specifically address the tolerability of ARBs in older patients, it is important to mention that several clinical trials have demonstrated that ARBs are well tolerable and the risk of discontinuation is similar to placebo. [10] [11] [12] [13] limitations Our study has several limitations. Since we required the mean age of patients in the individual studies to be 65 years or older, many would be <65 years of age. Unfortunately, we could not conduct an analysis including only patients aged 65 years or older since we had no access to patient level data. Moreover, the studies did not conduct subgroup analyses according to age. Despite this limitation, our results are valid among patients with a mean age of 68 years of age. Second, the defining age for older patients is not standardized; we used the age of 65 years as our cutoff since it is the age used by the World Health Organization and the American College of Cardiology/American Heart Association for defining the elderly. Third, several outcomes had significant heterogeneity, which may have been as a result of including different ARBs, difference in the types of the controls used, and variation in the doses and duration of treatment. In order to overcome this effect, we did a sensitivity analysis for placebo-only as the control and this showed a reduction in the observed heterogeneity for most of the outcomes. Fourth, we constructed our analysis based on the assumption that all ARBs have a similar class effect, but it is important to mention that pharmacological differences do exist between the various ARBs, 36 though no firm data indicate that these differences have any impact on clinical outcomes. Fifth, the outcomes reported in our analysis were not consistently defined in the trials, which is a limitation in most meta-analyses and can attribute to some degree of heterogeneity in the outcomes reported.
Our meta-analysis that included patients with mean age of 65 years or older with a high prevalence of heart failure suggested that ARBs are associated with a reduction in the risk of stroke. There were no (or weak associations) of ARBs on all-cause mortality, nonfatal MI, and/or heart failure hospitalization. However, ARBs were associated with a higher risk of acute kidney injury, hypotension, and hyperkalemia compared to placebo or control agent; thus, they should be used with caution when clinically indicated in this age group.
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